Cost effectiveness of amoxicillin for lower respiratory tract infections in primary care: an economic evaluation accounting for the cost of antimicrobial resistance -

Cost effectiveness of amoxicillin for lower respiratory tract infections in primary care: an economic evaluation accounting for the cost of antimicrobial resistance
Information type: Other primary research
Source: British Journal of General Practice
Specialities: Infection and infectious diseases | Respiratory disorders
Summary
Analysis found amoxicillin is associated with cost-effectiveness ratio of £6540/QALY gained, showing cost-effectiveness if cost of resistance (CR) is ignored. However if the CR is considered (including societal costs), it is associated with an ICER ranging from £12000-590000/QALY
UKMi comment
Authors of this report highlight that economic evaluation of antibiotic prescribing strategies that do not include the cost of resistance may provide misleading results that could be of questionable use to policymakers.
Related links: